kabutan

ZERIA PHARMACEUTICAL CO.,LTD., First Half Ordinary Profit Increases by 45%, July-September Ordinary Profit Increases by 16%

Wed Nov 6, 2024 4:00 pm JST Earnings

4559 ZERIA PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

ZERIA PHARMACEUTICAL CO.,LTD. <4559> [TSE-P] announced its financial results after the market closed on November 6th (16:00). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2025 (April to September) expanded to 7.94 billion yen, an increase of 44.7% compared to the same period last year. The progress rate against the 11 billion yen full-year plan was 72.3%, also surpassing the five-year average of 53.6%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to grow by 1.1% from the same period last year, reaching 3.05 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit grew by 16.4% from the same period last year, reaching 2.49 billion yen. However, the operating profit margin decreased from 12.8% in the same period last year to 12.0%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2022 33,712 5,894 5,182 3,998 90.4 68.4 Nov 2, 2022 J-GAAP
Apr - Sep, 2023 36,678 5,327 5,495 5,396 122.4 64.5 Nov 1, 2023 J-GAAP
Apr - Sep, 2024 42,422 6,459 7,949 6,061 137.5 72.3 Nov 6, 2024 J-GAAP
YoY +15.7% +21.3% +44.7% +12.3% +12.3%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 Guidance 42,420 6,450 7,940 6,060 137.5 23 Nov 5, 2024 J-GAAP
Apr - Sep, 2024 Results 42,422 6,459 7,949 6,061 137.5 23 Nov 6, 2024 J-GAAP
Revision Rate +0.0% +0.1% +0.1% +0.0% +0.0%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 39,047 4,294 3,018 2,335 53.0 22 May 9, 2024 J-GAAP
Oct - Mar, 2024 Guidance 43,578 4,541 3,051 2,439 55.3 23 Nov 6, 2024 J-GAAP
YoY +11.6% +5.8% +1.1% +4.5% +4.5%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 68,383 9,014 7,579 6,195 140.3 40 May 11, 2023 J-GAAP
Mar, 2024 75,725 9,621 8,513 7,731 175.4 44 May 9, 2024 J-GAAP
Mar, 2025 Guidance 86,000 11,000 11,000 8,500 192.8 46 Nov 5, 2024 J-GAAP
YoY +13.6% +14.3% +29.2% +9.9% +9.9%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2023 18,374 2,357 2,140 2,481 56.3 12.8 Nov 1, 2023 J-GAAP
Oct - Dec, 2023 21,241 4,163 3,949 3,027 68.7 19.6 Feb 1, 2024 J-GAAP
Jan - Mar, 2024 17,806 131 -931 -692 -15.7 0.7 May 9, 2024 J-GAAP
Apr - Jun, 2024 21,455 3,939 5,459 4,212 95.6 18.4 Aug 1, 2024 J-GAAP
Jul - Sep, 2024 20,967 2,520 2,490 1,849 42.0 12.0 Nov 6, 2024 J-GAAP
YoY +14.1% +6.9% +16.4% -25.5% -25.5%

Related Articles